Balyasny Asset Management
RNAC icon

Balyasny Asset Management’s Cartesian Therapeutics RNAC Stock Holding History

Balyasny Asset Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-49,497
Closed -$798K – 3187
2024
Q3 		$798K Buy
+49,497
New +$773K ﹤0.01% 2053
2023
Q2 		– Sell
-1,631
Closed -$68K – 2715
2023
Q1 		$68K Buy
1,631
+940
+136% +$44.2K ﹤0.01% 2353
2022
Q4 		$23.4K Buy
+691
New +$29.4K ﹤0.01% 2464
2022
Q3 		– Sell
-788
Closed -$31K – 3207
2022
Q2 		$31K Buy
+788
New +$23.4K ﹤0.01% 2419
2018
Q2 		– Sell
-755
Closed -$231K – 2093
2018
Q1 		$231K Sell
755
-77
-9% -$21.9K ﹤0.01% 1714
2017
Q4 		$245K Buy
+832
New +$364K ﹤0.01% 1822

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management's RNAC Position: Q4 2024 in Review

Balyasny Asset Management sold out of Cartesian Therapeutics (RNAC) in Q4 2024, closing a stake of 49,497 shares — an estimated $798K sold.

Balyasny Asset Management first reported a position in RNAC in Q4 2017 and held it in 6 quarters. The position peaked at $798K in Q3 2024. 68 funds tracked by Wall St. Rank hold RNAC as of Q4 2024.

  • Balyasny Asset Management reported no remaining Cartesian Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 49,497 Cartesian Therapeutics shares in Q4 2024, an estimated $798K.
  • Balyasny Asset Management first reported a position in Cartesian Therapeutics in Q4 2017 and held it in 6 quarters.
  • Balyasny Asset Management's Cartesian Therapeutics position peaked at $798K in Q3 2024.
  • 68 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2024.

Based on Balyasny Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.